Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $42,810 | $25,902 | $31,418 |
| % Growth | -100% | 65.3% | -17.6% | – |
| Cost of Goods Sold | $0 | $41,801 | $2,780 | $2,368 |
| Gross Profit | $0 | $1,009 | $23,122 | $29,050 |
| % Margin | – | 2.4% | 89.3% | 92.5% |
| R&D Expenses | $8,151 | $41,801 | $52,982 | $66,656 |
| G&A Expenses | $5,944 | $16,853 | $16,394 | $16,593 |
| SG&A Expenses | $5,944 | $16,853 | $16,394 | $16,593 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $13,912 | -$8,173 | -$3,685 |
| Operating Expenses | $14,095 | $72,566 | $61,203 | $79,564 |
| Operating Income | $0 | -$29,756 | -$43,474 | -$51,831 |
| % Margin | – | -69.5% | -167.8% | -165% |
| Other Income/Exp. Net | $0 | $5,213 | $10,197 | $6,093 |
| Pre-Tax Income | -$17,434 | -$24,543 | -$33,277 | -$45,738 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,434 | -$24,543 | -$31,253 | -$43,366 |
| % Margin | – | -57.3% | -120.7% | -138% |
| EPS | -7.83 | -21.8 | -33.71 | -53.75 |
| % Growth | 64.1% | 35.3% | 37.3% | – |
| EPS Diluted | -7.83 | -21.8 | -33.71 | -53.75 |
| Weighted Avg Shares Out | 2,226 | 1,126 | 927 | 807 |
| Weighted Avg Shares Out Dil | 2,226 | 1,126 | 927 | 807 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,851 | $721 | $4 |
| Interest Expense | -$3,887 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1,781 | $2,780 | $2,368 |
| EBITDA | $0 | -$22,762 | -$32,521 | -$45,778 |
| % Margin | – | -53.2% | -125.6% | -145.7% |